Respiratory tract infection, most often involving opportunistic bacterial species with broad-spectrum antibiotic resistance, is the primary cause of death in persons with cystic fibrosis (CF). Species within the Burkholderia cepacia complex are especially problematic in this patient population. We investigated the activity of a novel surfactant-5 stabilized oil-in-water nanoemulsion (NB-401) for activity against 150 bacterial isolates, primarily recovered from CF respiratory tract specimens. These included 75
[ INTRODUCTION] For reasons that are not well understood, persons with cystic fibrosis (CF) are prone to chronic infection of the respiratory tract, which ultimately leads to pulmonary failure, 25 the primary cause of death in this patient population. Pathogenic bacterial species such as Staphylococcus aureus and Haemophilus influenzae are commonly involved in infection in young CF patients, while a growing number of opportunistic species causes infection in older individuals. Chief among these is Pseudomonas aeruginosa, which infects the majority of adults with CF. Several other species, although less frequently 30 recovered in CF, are particularly problematic due to their multi-drug resistant phenotypes. These include Achromobacter xylosoxidans and Stenotrophomonas maltophilia as well as several Ralstonia and Pandoraea species. The frequency of respiratory tract infection by these species increases with patient age, posing a significant health risk to the growing number of CF patients surviving to adulthood. 35 Seventy two (48%) of the remaining isolates were susceptible to at least one antibiotic, and susceptibility testing results were unavailable for 29 (19%) isolates. All isolates were identified to the species level at the BcRLR by polyphasic analyses using phenotypic and genotypic assays as described previously (48). The exception was 95
Acinetobacter, which was identified only to the genus level due to lack of definitive species-specific assays. All isolates were also subjected to repetitive extragenic element-PCR typing using the BOX A1R primer as previously described (15) Nanoemulsion. Nanoemulsion NB-401 was supplied by NanoBio Corp. (Ann Arbor, MI) and was manufactured by emulsification of cetylpyridinium chloride (CPC), Poloxamer 407, and ethanol in water with super-refined soybean oil using a high speed emulsifier. The resultant droplets had a mean particle diameter of 400 nm. The 105 surfactants and food substances used were 'Generally Recognized as Safe' (GRAS) by the FDA, and manufactured in accordance with Good Manufacturing Practices (GMP).
The concentration of CPC was used as a surrogate for the amount of NB-401 used experimentally. NB-401 was stable for no less than 12 months at temperatures up to To test nanoemulsion activity against biofilm cultures, isolates shown to produce biofilm by crystal violet staining were grown in triplicate for 48h as described above. 
RESULTS

190
NB-401 activity against planktonic bacteria. Due to the opaque white color of NB-401, the standard CLSI-approved microtiter serial dilution method was modified to include the addition of resazurin as an indicator of bacterial viability. NB-401 was tested in a concentration range of 15.6 -2000 µg/ml. MICs were defined as the lowest concentrations of NB-401 that did not produce color changes from blue to pink (Fig. 1) . 195
Comparison of these visual inflection points with fluorometric analyses showed that, based on growth in untreated positive control wells, 63% of MIC wells had ≤1% metabolic activity, 91% had ≤ 5% metabolic activity, and 96% had ≤10% metabolic activity. The MIC results are shown in Table 1 . All strains were inhibited by the concentrations of NB-401 tested. The MIC 50 for the entire panel of 150 strains was 31.2 200 µg/ml; the MIC 90 was 125 µg/ml. Thirty eight strains (25%) were inhibited by the lowest concentration of NB-401 tested (15.6 µg/ml), and only a single strain each required a concentration of 250 µg/ml and 500 µg/ml for inhibition. NB-401 was slightly more active against non-Burkholderia strains (MIC 50 31 .2 µg/ml; MIC 90 62.5 µg/ml) than Burkholderia strains (MIC 50 62.5 µg/ml; MIC 90 125 µg/ml) ( showed time-and concentration-dependent killing, with a 99% decrease in bacterial 215 viability within 90 min at a NB-401 concentration two times greater than the MIC and complete killing within 30 min at concentrations eight times greater than the MIC ( Fig   3A) .
NB-401 activity against bacteria grown in biofilm.
To assess further the activity of NB-401, bacteria were grown as biofilms. Twelve biofilm-forming strains were 220 identified from crystal violet staining of 25 strains from the test panel. The median increase in MBICs compared to the respective MICs of NB-401 for these strains was eight-fold. Nine (75%) of the 12 strains showed decreased susceptibility, defined as at least a four-fold increase in the MBIC compared to the MIC (Table 2 ). Similar to planktonic bacteria, biofilm bacteria did not exhibit evidence of tolerance to NB-401; 225
MBECs were identical to their respective MBICs for 10 of the 12 strains. (Table 2) . Nevertheless, NB-401 showed antibacterial activity against all strains in the presence of sputum. MICs in the presence of sputum were not determined since sputum was inherently fluorescent and masked the fluorescence emitted by the reduction of resazurin. CF sputum inhibited the activity of NB-401 against planktonic 235 bacteria in a concentration dependent manner (Fig. 3B) .
DISCUSSION
Although the bacterial species we included in this study are generally not virulent in We focused our investigation of NB-401 on species within the Bcc, as infection with these species is particularly refractory to antimicrobial therapy and associated with increased rates of morbidity and mortality in CF (7). Importantly, infection with Bcc is also regarded by many CF care centers as an absolute contraindication to lung 280 transplantation (34) . Because B. multivorans and B. cenocepacia account for the majority of Bcc infection in CF (48), we included relatively more strains from these two species. We also included B. gladioli, which although not a member of the Bcc, is being recovered with increasing frequency from CF patients (4). The numbers of strains included in our test panel from the remaining species were also chosen to reflect the 285 relative proportion of these species recovered from CF patients. The exception is Acinetobacter, which although currently infrequently recovered in CF, appears to be an emerging pathogen in this patient population. The majority (94%) of isolates in the test panel were recovered from cultures of respiratory specimens from persons with CF.
The panel also included one representative isolate from each of five previously 290 described so-called epidemic lineages, each of which has been identified as infecting multiple CF patients. These included the B. cenocepacia ET12 (29) µg/ml) were found among non-Burkholderia species. We observed no striking differences in NB-401 activity among the 10 Burkholderia species examined, although the two strains requiring the highest MICs (250 µg/ml and 500 µg/ml) were both B.
cenocepacia. Among the non-Burkholderia species, NB-401 was most active against
Ralstonia strains (MIC 90 ≤15.6 µg/ml) and relatively less active against Acinetobacter 310 strains (MIC 90 = 125 µg/ml). We found no evidence of tolerance to NB-401 among a subset of 34 strains for which both MIC and MBC were determined. NB-401 killing of planktonically grown bacteria was time-and concentration-dependent; at a concentration 8 times greater than the MIC, complete killing was achieved within 30 min. This suggests that a relatively brief exposure of bacteria to NB-401 could result in 315 a significant decrease in viable bacteria during therapy.
While we found NB-401 to be highly active against a rigorously assembled panel of CF-associated bacteria, the relevance of standard susceptibility testing of planktonically grown bacteria to the treatment of infections involving bacteria within biofilms has been questioned recently. Several species involved in CF infection, including P. aeruginosa 320 and Burkholderia, have the capacity to produce biofilms in vitro, and emerging evidence strongly suggests that biofilm formation within the airways of infected patients contributes to disease progression and persistence of infection (20, 39, 50, 51) .
A C C E P T E D
Furthermore, sessile bacteria within biofilms demonstrate increased antimicrobial resistance relative to their planktonic counterparts (9, 17, 41, 54) . We therefore sought 325 to assess the activity of NB-401 against bacteria grown in vitro as biofilms. Using a relatively strict definition of in vitro biofilm formation to ensure a stringent test of NB-401 activity, 12 biofilm-forming strains representing several species and a range of planktonic susceptibilities to NB-401 were identified. As there is currently no standardized protocol for susceptibility testing of bacteria in biofilm, we considered the 330 merits of various published methods (9-11, 17, 41, 44-46, 53, 57) and tested a number of variables to develop a combination of steps that we believed were best suited for our study, particularly considering the opacity of the nanoemulsion. These included comparing inoculum volumes and concentrations, peg versus well surfaces for biofilm growth, durations of biofilm growth, spectrophotometric versus colorimetric 335 measurements, and various methods to suspend biofilm bacteria after treatment, CF sputum, like biofilm, is reported to antagonize the activity of antibacterial drugs (28) . Glycoproteins and high molecular weight DNA are present in elevated levels resulting in exceptionally viscous sputum that provides a physical barrier protecting bacteria. In addition, these macromolecules bind and sequester antibiotics while small 355 cationic molecules and the decreased pH of CF sputum block drug penetration into bacteria and reduce drug bioactivity. The strategy of increasing drug dosing to overcome these obstacles is limited by drug toxicity. To assess the impact of sputum on the antibacterial activity of NB-401, we repeated the standard planktonic testing for the 12 biofilm-forming strains in the presence of CF sputum. We used a mixture of 360 sputum from 15 CF patients to avoid inter-patient variation in macromolecule and high molecular weight DNA composition, and in ionic conditions, and only applied mechanical shearing to minimize changes to the native microenvironment (22) . The activity of NB-401 against bacteria suspended in media containing 43% sputum (the maximum sputum concentration achieved in out test system) was decreased with 365 bactericidal concentrations 2-to 32-fold greater than the respective planktonic MBCs In summary, the results of this study support a potential role for NB-401 as an antimicrobial treatment for infection due to CF-related opportunistic pathogens. Most strains tested, including many multi-and pan-resistant strains, were inhibited in vitro by a ≤ 125 µg/ml of NB-401 (a 16-fold dilution of the nanoemulsion). This emulsion was rapidly bactericidal and was active against bacteria whether grown planktonically, as 375 biofilm, or in the presence of CF sputum. In ongoing work, we have found nanoemulsions to be exceptionally stable, unchanged after nebulization, and broadly microbicidal. Importantly, we have not observed the development of resistance to NB-401 by any bacterial species examined to date. Comprehensive Phase II clinical safety, tolerability and pharmacokinetic studies of similar nanoemulsion formulations for use as 380 topical therapeutics for herpes labilis and onychomycosis have shown these formulations (NB-001 and NB-002, respectively) to be safe and well tolerated as described previously (30, 31) . Nasal application of similar nanoemulsions as vaccine delivery agents were well tolerated and did not induce inflammation in mice (6, 42) , and a recent pre-clinical safety evaluation of a nanoemulsion vaccine adjuvant similarly 385 showed no inflammation, cytotoxicity or systemic toxicity with mucosal application (36) . 
